Immune System News and Research

RSS

Study reveals expansion of NK cells after acute infection

The natural killer cells of our immune defense are activated for an extended period after the acute infection, which challenges the prevailing view that the elevation and activation of cells quickly pass.

3 Mar 2011

Groundbreaking discovery in lymphoma research

BC Cancer Agency scientists have discovered that a single gene, CIITA, is implicated in almost 40 per cent of primary mediastinal B-cell lymphomas and 15 per cent of all Hodgkin lymphoma cases.

3 Mar 2011

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

Vical Incorporated announced today the receipt of Scientific Advice from the European Medicines Agency (EMA) recommending practical efficacy endpoints for a Phase 3 trial of the company's TransVax™ therapeutic cytomegalovirus (CMV) vaccine.

3 Mar 2011

New breakthrough in immunological research

Immunological research at the University of Haifa, Israel, has made a new breakthrough, revealing a critical component in the "decision-making" process of white blood cells that play a role in the healing process from bacterial inflammation.

3 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

3 Mar 2011

FADD protein discovery can lead to better cancer and autoimmune disease drugs

Reporting in Nature, scientists from Thomas Jefferson University have determined that a single protein called FADD controls multiple cell death pathways, a discovery that could lead to better, more targeted autoimmune disease and cancer drugs.

3 Mar 2011

Scientists provide new insight into mechanisms controlling programmed cell death pathways

Work led by St. Jude Children's Research Hospital investigators provides fresh insight into mechanisms controlling programmed cell death pathways and offers new targets in the fight against cancer and virus-infected cells

3 Mar 2011

New microfluidic device may help clinicians to improve cancer therapy

Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.

3 Mar 2011

IAVI, THSTI collaborate to establish HIV Vaccine Design Program in India

The Translational Health Sciences and Technology Institute, an autonomous institute of the Indian government's Department of Biotechnology, and the International AIDS Vaccine Initiative announced today an agreement to jointly establish, operate and fund an HIV Vaccine Design Program in India.

2 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV). The study determined that the presence of G-allele serves as a marker for severe HCV-induced graft inflammation, as well as a predictor for unsuccessful treatment. Study findings—the largest to report on the role IL28B variants in a transplant cohort with recurrent HCV—are published in the March issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

2 Mar 2011

Oxygen Biotherapeutics receives U.S. Army grant for studies of Oxycyte

Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT) today announced it has received a $2,075 million two-year grant from the U.S. Army to study the Company’s proprietary Oxycyte® PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury (TBI).

2 Mar 2011

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

An analysis of immune markers measured in a sub-study of ViroStatics' proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load.

2 Mar 2011

U.S. Army awards Oxygen Biotherapeutics two-year grant to study Oxycyte PFC emulsion against TBI

Oxygen Biotherapeutics, Inc. today announced it has received a $2.075 million, two-year grant from the U.S. Army to study the Company's proprietary Oxycyte PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury.

2 Mar 2011

New insight into HIV/AIDS

A paper published in the March 2011 print edition of the Journal of Clinical Investigation offers new insight into what prompts immunity to AIDS in sooty mangabeys, a natural host African monkey species.

2 Mar 2011

Vaccine-induced cellular immune responses against HIV-1 infection exert selective pressure on the virus

An AIDS vaccine tested in people, but found to be ineffective, influenced the genetic makeup of the virus that slipped past. The findings suggest new ideas for developing HIV vaccines.

2 Mar 2011

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

An experimental drug that targets a brain system that controls inflammation might help preserve neurological function in people who survive sudden cardiac arrest, new research suggests.

2 Mar 2011

Regular exercise cuts risk of bowel cancer

People with an active lifestyle are up to three times less likely to develop large or advanced polyps in the bowel - which can develop into bowel cancer - according to a new analysis published in the British Journal of Cancer today (Wednesday).

1 Mar 2011

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.

1 Mar 2011

VaxInnate receives $196 million BARDA contract to develop novel flu vaccines

VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.

1 Mar 2011

Study: Happy people tend to live longer and experience better health

A review of more than 160 studies of human and animal subjects has found "clear and compelling evidence" that - all else being equal - happy people tend to live longer and experience better health than their unhappy peers.

1 Mar 2011

Immune System News and Research

Study reveals expansion of NK cells after acute infection

Groundbreaking discovery in lymphoma research

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

New breakthrough in immunological research

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

FADD protein discovery can lead to better cancer and autoimmune disease drugs

Scientists provide new insight into mechanisms controlling programmed cell death pathways

New microfluidic device may help clinicians to improve cancer therapy

IAVI, THSTI collaborate to establish HIV Vaccine Design Program in India

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Oxygen Biotherapeutics receives U.S. Army grant for studies of Oxycyte

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

U.S. Army awards Oxygen Biotherapeutics two-year grant to study Oxycyte PFC emulsion against TBI

New insight into HIV/AIDS

Vaccine-induced cellular immune responses against HIV-1 infection exert selective pressure on the virus

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

Regular exercise cuts risk of bowel cancer

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

VaxInnate receives $196 million BARDA contract to develop novel flu vaccines

Study: Happy people tend to live longer and experience better health

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News